InflaRx N.V. — 2017 Form 20-F Summary
Reporting period: Fiscal year ended December 31, 2017. This is an annual report, not a standalone fourth-quarter filing. Financial statements are audited and prepared under IFRS in euros. InflaRx is a clinical-stage biopharmaceutical company developing anti-C5a therapies; it had no product revenue.
Key financial metrics
| Metric | 2017 | 2016 |
|---|---|---|
| Revenue from product sales | None | None |
| Other income, net | €0.108 million | €0.231 million |
| Research and development expense | €14.415 million | €5.278 million |
| General and administrative expense | €5.138 million | €1.844 million |
| Net finance costs | €4.793 million | €2.048 million |
| Net loss | €24.238 million | €8.939 million |
| Basic and diluted loss per share | €2.60 | €3.80 |
| Net cash used in operating activities | €12.152 million | €4.992 million |
| Cash and cash equivalents, year-end | €123.282 million | €29.117 million |
| Total assets, year-end | €124.213 million | €29.518 million |
| Total liabilities, year-end | €4.784 million | €55.207 million |
| Total equity, year-end | €119.429 million | Negative €25.689 million |
Margins are not meaningful because the company reported no product revenue. Income tax expense was zero. The filing reports no conventional borrowings; preferred shares previously presented as liabilities converted into common equity in the 2017 reorganization and IPO. Year-end liabilities were principally current payables and other liabilities.
Business developments and outlook
- InflaRx’s lead candidate, IFX-1, is an intravenous anti-C5a antibody. It was in Phase IIb development for hidradenitis suppurativa (HS); the FDA accepted the IND in January 2018 and patient enrollment began in February 2018. The planned randomized study targets approximately 175 patients, with a 16-week placebo-controlled period and an open-label extension.
- In a 12-patient, single-center, open-label Phase IIa HS study, 75% had a HiSCR response at day 50 and 83% at day 134. Management cautioned that these early findings require confirmation in larger controlled trials.
- The company planned to begin Phase II development of IFX-1 for ANCA-associated vasculitis (AAV) in the second or third quarter of 2018. IFX-2 remained in early preclinical development, intended for chronic inflammatory conditions.
- Management expected 2018 R&D costs to rise substantially as HS and AAV trials advanced. It estimated that a potential Phase III HS program could cost €40–€50 million. Management said existing cash should fund operating and capital requirements for at least 24 months, while also stating additional funding would be needed to advance development and any commercialization.
Material changes, unusual items, and risks
- Net loss widened by €15.299 million year over year, mainly as R&D spending increased €9.137 million and G&A increased €3.294 million. R&D growth reflected trial preparation, manufacturing and personnel costs; G&A growth included IPO and Nasdaq-related expenses.
- Operating cash use increased to €12.152 million. Financing activities provided €108.801 million, principally from preferred-share financings and the IPO. Cash also reflected a €2.317 million negative exchange-rate effect.
- The November 2017 IPO raised approximately $106 million gross and $96 million net. The corporate reorganization made InflaRx N.V. the holding company for InflaRx GmbH; the historical financial statements continue those of InflaRx GmbH. Preferred-share conversion and IPO-related accelerated vesting contributed to material balance-sheet and expense changes.
- Net finance costs included €2.229 million of preferred-share interest and €2.358 million of unrealized foreign-exchange losses. Share-based payment expense was €4.550 million, with accelerated vesting of prior awards upon the IPO contributing to the increase.
- Contractual lease and CRO commitments totaled €5.249 million at year-end, of which €4.679 million was due within one year. Most other CRO and clinical-site contracts were terminable on notice and excluded from this total.
- Key risks include clinical-trial failure or delay, the unproven C5a-targeting approach, dependence on IFX-1, regulatory and patient-enrollment uncertainty, reliance on third-party manufacturers and CROs, future financing needs, competition, intellectual-property challenges, and euro/U.S.-dollar exposure. The company had no currency hedging arrangements. No material litigation was reported for the period.
- The company discontinued development of IFX-1 for complex cardiac surgery after high trial variability and no statistically significant effect on IL-6; it also prioritized HS and AAV over sepsis development.
Important facts for investors to verify
- Check subsequent disclosures for Phase IIb HS enrollment, endpoint results, safety findings, and whether the stated development timelines changed.
- Verify cash burn and runway against the pace and cost of HS and AAV trials, and assess when additional financing may be required.
- Review the audited financial statements and notes for IPO/reorganization accounting, preferred-share conversion, share-based compensation, and foreign-exchange exposure.
- Confirm the status and terms of manufacturing supply, CRO commitments, patent applications, and the China co-development arrangement.
- Assess dilution and governance considerations, including outstanding options, shareholder concentration, registration rights, and the company’s Dutch-incorporated foreign-private-issuer status.